At Zealand Pharma, we are a Danish biotechnology company on a mission to change lives with next generation peptide medicines. In our effort to reach our goals, bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other. Ten drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market. Our current pipeline of internal product candidates focuses on obesity, chronic inflammation, and certain rare diseases. Our leading obesity programs are backed by strong partners, including Roche and Boehringer Ingelheim. We are based in Copenhagen (Søborg), Denmark, with a team in the U.S. For further information about our business and activities, please visit www.zealandpharma.com or bond with us through LinkedIn.
Looking for a particular Zealand Pharma employee's phone or email?
The Zealand Pharma annual revenue was $52.4 million in 2026.
Adam Steensberg is the President and CEO of Zealand Pharma.
408 people are employed at Zealand Pharma.
Zealand Pharma is based in Copenhagen, South Denmark.
The NAICS codes for Zealand Pharma are [54, 32, 54171, 325, 541, 541714, 5417, 3254].
The SIC codes for Zealand Pharma are [283, 873, 28, 87].